NCT04892654View on ClinicalTrials.gov

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions
HIV-1-infection
Interventions
DRUG

Doravirine

Antiretroviral, Non-nucleoside Reverse Transcriptase Inhibitor

DRUG

Dolutegravir

Antiretroviral, Integrase strand transfer inhibitors

OTHER

Triple cART regimen

Participant standard triple cART regimen

Trial Locations (3)

NW1 0PE

RECRUITING

Mortimer Market Centre, London

SW10 9NH

RECRUITING

Chelsea & Westminster Hospital NHS Foundation Trust, London

Unknown

RECRUITING

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
lead

Chelsea and Westminster NHS Foundation Trust

OTHER